tetano
Editor, Senior Moderator
J Thromb Thrombolysis
. 2021 Sep 14.
doi: 10.1007/s11239-021-02560-x. Online ahead of print.
Immature platelets in patients with Covid-19: association with disease severity
Amir Cohen[SUP] 1 2 [/SUP], Emanuel Harari[SUP] 1 2 [/SUP], Ella Yahud[SUP] 1 2 [/SUP], Michal Cipok[SUP] 2 3 [/SUP], Gabriel Bryk[SUP] 2 3 [/SUP], Nili Karp Lador[SUP] 2 4 [/SUP], Tal Mann[SUP] 2 4 [/SUP], Ami Mayo[SUP] 2 4 [/SUP], Eli I Lev[SUP] 5 6 7 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (Covid-19) is associated with a high incidence of venous and arterial thromboembolic events. Currently, there are no clinical or laboratory markers that predict thrombotic risk. Circulating immature platelets are hyper-reactive platelets, which are associated with arterial thrombotic events. The aim of this study was to assess whether the proportion of circulating immature platelets is associated with disease severity in Covid-19 patients. Patients admitted with Covid-19 disease were prospectively assessed. Immature platelet count (IPC) and immature platelet fraction (IPF) were measured at admission and at additional time points during the hospital course using the Sysmex XN-3000 auto-analyzer. A total of 136 consecutive patients with Covid-19 were recruited [mean age 60 ± 19 years, 49% woman, 56 (41%) had mild-moderate disease and 80 (59%) had severe disease at presentation]. The median IPF% was higher in patients with severe compared to mild-moderate disease [5.8 (3.9-8.7) vs. 4.2 (2.73-6.45), respectively, p = 0.01]. The maximal IPC value was also higher in patients with severe disease [15 (10.03-21.56), vs 10.9 (IQR 6.79-15.62), respectively, p = 0.001]. Increased IPC was associated with increased length of hospital stay. Patients with severe Covid-19 have higher levels of IPF than patients with mild-moderate disease. IPF may serve as a prognostic marker for disease severity in Covid-19 patients.
Keywords: Coronavirus disease 2019; Immature platelets; Platelet aggregation inhibitors; Reticulated platelets; SARS-CoV-2 infection; thrombosis.
. 2021 Sep 14.
doi: 10.1007/s11239-021-02560-x. Online ahead of print.
Immature platelets in patients with Covid-19: association with disease severity
Amir Cohen[SUP] 1 2 [/SUP], Emanuel Harari[SUP] 1 2 [/SUP], Ella Yahud[SUP] 1 2 [/SUP], Michal Cipok[SUP] 2 3 [/SUP], Gabriel Bryk[SUP] 2 3 [/SUP], Nili Karp Lador[SUP] 2 4 [/SUP], Tal Mann[SUP] 2 4 [/SUP], Ami Mayo[SUP] 2 4 [/SUP], Eli I Lev[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 34519015
- DOI: 10.1007/s11239-021-02560-x
Abstract
Coronavirus disease 2019 (Covid-19) is associated with a high incidence of venous and arterial thromboembolic events. Currently, there are no clinical or laboratory markers that predict thrombotic risk. Circulating immature platelets are hyper-reactive platelets, which are associated with arterial thrombotic events. The aim of this study was to assess whether the proportion of circulating immature platelets is associated with disease severity in Covid-19 patients. Patients admitted with Covid-19 disease were prospectively assessed. Immature platelet count (IPC) and immature platelet fraction (IPF) were measured at admission and at additional time points during the hospital course using the Sysmex XN-3000 auto-analyzer. A total of 136 consecutive patients with Covid-19 were recruited [mean age 60 ± 19 years, 49% woman, 56 (41%) had mild-moderate disease and 80 (59%) had severe disease at presentation]. The median IPF% was higher in patients with severe compared to mild-moderate disease [5.8 (3.9-8.7) vs. 4.2 (2.73-6.45), respectively, p = 0.01]. The maximal IPC value was also higher in patients with severe disease [15 (10.03-21.56), vs 10.9 (IQR 6.79-15.62), respectively, p = 0.001]. Increased IPC was associated with increased length of hospital stay. Patients with severe Covid-19 have higher levels of IPF than patients with mild-moderate disease. IPF may serve as a prognostic marker for disease severity in Covid-19 patients.
Keywords: Coronavirus disease 2019; Immature platelets; Platelet aggregation inhibitors; Reticulated platelets; SARS-CoV-2 infection; thrombosis.